JP5281895B2 - カルシウム吸収促進剤 - Google Patents

カルシウム吸収促進剤 Download PDF

Info

Publication number
JP5281895B2
JP5281895B2 JP2008539175A JP2008539175A JP5281895B2 JP 5281895 B2 JP5281895 B2 JP 5281895B2 JP 2008539175 A JP2008539175 A JP 2008539175A JP 2008539175 A JP2008539175 A JP 2008539175A JP 5281895 B2 JP5281895 B2 JP 5281895B2
Authority
JP
Japan
Prior art keywords
calcium
oral composition
gum arabic
absorption
intake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008539175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526748A (ja
JP2009526748A5 (https=
Inventor
秀秋 松田
正宏 岩城
篤史 川瀬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virimed Uk Ltd
Original Assignee
Virimed Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virimed Uk Ltd filed Critical Virimed Uk Ltd
Priority to JP2008539175A priority Critical patent/JP5281895B2/ja
Publication of JP2009526748A publication Critical patent/JP2009526748A/ja
Publication of JP2009526748A5 publication Critical patent/JP2009526748A5/ja
Application granted granted Critical
Publication of JP5281895B2 publication Critical patent/JP5281895B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
JP2008539175A 2006-02-17 2007-02-13 カルシウム吸収促進剤 Expired - Fee Related JP5281895B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008539175A JP5281895B2 (ja) 2006-02-17 2007-02-13 カルシウム吸収促進剤

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US77437406P 2006-02-17 2006-02-17
US60/774,374 2006-02-17
JP2006041158 2006-02-17
JP2006041158 2006-02-17
PCT/JP2007/052906 WO2007094486A1 (en) 2006-02-17 2007-02-13 Accelerating agent of calcium absorption
JP2008539175A JP5281895B2 (ja) 2006-02-17 2007-02-13 カルシウム吸収促進剤

Publications (3)

Publication Number Publication Date
JP2009526748A JP2009526748A (ja) 2009-07-23
JP2009526748A5 JP2009526748A5 (https=) 2010-02-12
JP5281895B2 true JP5281895B2 (ja) 2013-09-04

Family

ID=38042502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008539175A Expired - Fee Related JP5281895B2 (ja) 2006-02-17 2007-02-13 カルシウム吸収促進剤

Country Status (15)

Country Link
US (2) US20090098222A1 (https=)
EP (2) EP1986566B1 (https=)
JP (1) JP5281895B2 (https=)
KR (1) KR20080103528A (https=)
CN (2) CN101431959A (https=)
AR (1) AR059577A1 (https=)
AT (1) ATE535283T1 (https=)
AU (1) AU2007215753B2 (https=)
BR (1) BRPI0708061A2 (https=)
CA (1) CA2642248A1 (https=)
MY (1) MY147271A (https=)
RU (1) RU2428193C2 (https=)
SG (1) SG169979A1 (https=)
TW (1) TW200800292A (https=)
WO (1) WO2007094486A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007039310A1 (de) * 2007-08-13 2009-02-19 Eberhard-Karls-Universität Tübingen Universitätsklinikum Zusammensetzung zur Prophylaxe und Behandlung von Osteoporose
WO2010008786A2 (en) * 2008-06-23 2010-01-21 Amano Enzyme Usa, Ltd. Enzymatic methods of flavor modification
EP2836083B1 (en) 2012-04-10 2016-08-03 Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG Wet granulation process and granulate material comprising arabic gum
CN107929313B (zh) * 2017-11-21 2021-02-19 上海金城素智药业有限公司 用于预防和治疗钙缺乏症的天然型牡蛎碳酸钙制剂及其制备方法
IT201900023016A1 (it) * 2019-12-04 2021-06-04 Alesco Srl Formulazioni comprendenti un minerale e un polisaccaride, loro composizioni e loro uso nella supplementazione di detto minerale
US20250228900A1 (en) * 2024-01-11 2025-07-17 Bios-Therapy, Physiological Systems For Health S.P.A. Natural matrix mixture for the treatment of bone fragility

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
WO1996031130A2 (en) * 1995-04-07 1996-10-10 Abbott Laboratories Calcium supplements and calcium containing beverages comprising vitamin d
US5609897A (en) * 1995-04-07 1997-03-11 Abbott Laboratories Powdered beverage concentrate or additive fortified with calcium and vitamin D
JP4493736B2 (ja) 1995-09-01 2010-06-30 日本水産株式会社 キチンを含有するミネラル吸収促進性組成物およびミネラル吸収促進用添加剤
US5855936A (en) * 1997-03-21 1999-01-05 Nestec S.A. Food fortification
CN1090006C (zh) * 1997-03-24 2002-09-04 丸尾钙株式会社 食品添加剂料浆组合物和粉末组合物以及含该添加剂的食品组合物
JPH11313634A (ja) * 1998-03-12 1999-11-16 Internatl Flavors & Fragrances Inc <Iff> 呈味剤とその製造方法
EP0960572A1 (en) * 1998-05-12 1999-12-01 N.V. Nutricia Nutritional composition for the treatment of pressure ulcers
JP2000026283A (ja) * 1998-07-10 2000-01-25 Nisshin Oil Mills Ltd:The 油性組成物を含有した粉末組成物
US6455082B1 (en) * 1999-04-26 2002-09-24 Nestec S.A. Shelf-stable calcium fortified milk and dairy products
JP2001186863A (ja) * 2000-01-05 2001-07-10 Maruo Calcium Co Ltd 食品添加剤スラリー組成物及びパウダー組成物、及びこれを含有する食品組成物
JP3563343B2 (ja) 2000-11-10 2004-09-08 株式会社東洋新薬 カルシウム利用効率が向上した食物繊維含有食品
JP2002223737A (ja) * 2001-02-02 2002-08-13 Dai Ichi Kogyo Seiyaku Co Ltd カルシウム強化飲料用分散剤、及びカルシウム含有粉末
JP4390428B2 (ja) * 2001-05-01 2009-12-24 株式会社林原生物化学研究所 含カルシウム組織強化剤
DE10127897B4 (de) * 2001-06-08 2006-04-20 Bionorica Ag Manteltablette mit Pflanzentrockenextrakten
US20030203097A1 (en) * 2002-04-24 2003-10-30 The Procter & Gamble Company Acidic compositions comprising protein and fiber and processes of their preparation
US7138151B2 (en) * 2002-11-22 2006-11-21 Unilab Pharmatech, Ltd. Calcium-fortified acidic beverages
JP2004292382A (ja) * 2003-03-27 2004-10-21 Kirin Brewery Co Ltd ミネラル吸収促進剤及び骨粗鬆症用予防及び／又は改善剤
JP2005047820A (ja) * 2003-07-29 2005-02-24 Taiyo Kagaku Co Ltd 整腸用組成物
KR20030078050A (ko) * 2003-09-01 2003-10-04 주식회사 엠에스씨 고분산성 유청칼슘 조성물 및 그 제조방법
CN1833727B (zh) * 2005-03-18 2010-07-28 潘思源 阿拉伯树胶在建立动物模型和降低血胆固醇中的用途
US20070003671A1 (en) * 2005-07-01 2007-01-04 Anglea Timothy A Two-part calcium fortified compositions and methods of making the same
CN101484146A (zh) * 2006-05-23 2009-07-15 奥拉黑尔斯公司 木糖醇锭剂及其用法

Also Published As

Publication number Publication date
US20090098222A1 (en) 2009-04-16
CN102755374A (zh) 2012-10-31
ATE535283T1 (de) 2011-12-15
US20110045014A1 (en) 2011-02-24
SG169979A1 (en) 2011-04-29
MY147271A (en) 2012-11-30
JP2009526748A (ja) 2009-07-23
AU2007215753B2 (en) 2013-04-18
AU2007215753A1 (en) 2007-08-23
RU2008137129A (ru) 2010-03-27
EP2298276A1 (en) 2011-03-23
TW200800292A (en) 2008-01-01
WO2007094486A1 (en) 2007-08-23
AR059577A1 (es) 2008-04-16
CA2642248A1 (en) 2007-08-23
CN101431959A (zh) 2009-05-13
RU2428193C2 (ru) 2011-09-10
KR20080103528A (ko) 2008-11-27
EP1986566B1 (en) 2011-11-30
BRPI0708061A2 (pt) 2011-05-17
EP2298276B1 (en) 2020-01-15
EP1986566A1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
JPH09291039A (ja) プロシアニジンを有効成分とする抗肥満剤
KR20080108523A (ko) 지방 축적 억제제
TW200848064A (en) Process for producing osteocalcin-containing extract
JP5281895B2 (ja) カルシウム吸収促進剤
US8722614B2 (en) Adiponectin production enhancer
JP6265335B2 (ja) 骨密度増加剤、破骨細胞活性抑制剤及び骨リモデリング改善剤
JP4494033B2 (ja) 血清コレステロール低下剤、飲食物およびその製造方法
JP5586713B2 (ja) ミネラル可溶化安定剤
JPH0767575A (ja) ミネラル吸収促進組成物
WO2004084919A1 (ja) 血中低分子量含窒素化合物の濃度を低減させる病態改善用食品
KR20070113460A (ko) 체중조절용 건강식품 조성물
JP2001269135A (ja) 体タンパク質蓄積効率を亢進する栄養組成物
JP4914594B2 (ja) 関節痛改善用食品組成物
JP6692183B2 (ja) 骨強化促進用組成物
JP2003277273A (ja) ミネラル吸収促進剤
ES2781428T3 (es) Agente acelerador de absorción de calcio
KR101306931B1 (ko) 골다공증 예방 효과를 가지는 유기태화 칼슘 강화 유단백질
JP2013126988A (ja) ミネラル吸収促進剤及び易吸収性カルシウム剤
JP5695098B2 (ja) 脂質代謝改善剤
JP2010095474A (ja) カルシウム吸収促進組成物及びカルシウム吸収促進飲食物
JP2007008920A (ja) 生活習慣病改善剤
JP2002080380A (ja) 骨形成促進剤
JPH11243914A (ja) カルシウム吸収促進飲食物
JP2013224277A (ja) 経口骨強化組成物及びそれを含有する飲食品、医薬又は飼料
JP2006104213A (ja) 血清コレステロールを低下させるために用いる飲食物およびその製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130527

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5281895

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees